David Neumann, MD
Gastroenterology · Oklahoma City, OKNPI 1043339575
Payments from drug & device makers
Across 493 payments — averaging $54.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$11K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- AbbVie$3K
- Shire North American Group Inc$1K
- Johnson & Johnson$552
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$309
- plus $3K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $10,500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 54 | $7,766 |
| AbbVie | 211 | $3,340 |
| Shire North American Group Inc | 5 | $1,186 |
| Johnson & Johnson | 36 | $552 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $309 |
| Gilead | 20 | $292 |
| Pfizer | 12 | $288 |
| Sanofi | 14 | $251 |
| Bristol Myers Squibb | 18 | $246 |
| Janssen Scientific Affairs, LLC | 2 | $246 |
| QOL Medical, LLC | 14 | $236 |
| Lilly USA, LLC | 10 | $212 |
| Regeneron Healthcare Solutions, Inc. | 8 | $161 |
| Daiichi Sankyo Inc. | 8 | $142 |
| Ardelyx, Inc. | 8 | $136 |
| Ipsen Biopharmaceuticals, Inc | 6 | $105 |
| Enterra Medical, Inc. | 1 | $80 |
| Ironwood Pharmaceuticals, Inc | 5 | $78 |
| Medtronic | 2 | $77 |
| Redhill Biopharma Inc. | 5 | $70 |
| Celltrion USA Inc. | 3 | $70 |
| Intercept Pharmaceuticals, Inc. | 5 | $62 |
| Nestle Healthcare Nutrition Inc. | 3 | $57 |
| Pharmacosmos Therapeutics Inc. | 3 | $55 |
| Aimmune Therapeutics, Inc. | 3 | $52 |
| Madrigal Pharmaceuticals | 2 | $50 |
| Ferring Pharmaceuticals Inc. | 2 | $33 |
| UCB, Inc. | 2 | $31 |
| Vivus LLC | 1 | $23 |
| Novo Nordisk | 1 | $20 |
| Merck | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
How this compares
$26,784 in reported general payments places this provider in the 80th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Oklahoma City
- Tauseef AliOklahoma City$2.1M
- David StokesberryOklahoma City$1.7M
- George SalemOklahoma City$1.2M
- Matthew McBrideOklahoma City$741K
- Richard HartyOklahoma City$462K
- Hussein BitarOklahoma City$184K
- Neil CrittendenOklahoma City$143K
- Pooja SinghalOklahoma City$140K
- Trushar PatelOklahoma City$49K
- Sumit WaliaOklahoma City$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.